# Effect of Intralymphatic Immunotherapy

> **NCT02255604** · PHASE2 · COMPLETED · sponsor: **University of Aarhus** · enrollment: 36 (actual)

## Conditions studied

- Allergy
- Immune Tolerance
- Injection Site Discomfort

## Interventions

- **DRUG:** Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
- **DRUG:** alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
- **DRUG:** 0.1 ml Isoton saline

## Key facts

- **NCT ID:** NCT02255604
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-09
- **Final completion:** 2017-02-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255604, "Effect of Intralymphatic Immunotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02255604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*